Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Overview of Chronic Inducible Urticaria: Diagnosis, Triggers, and Emerging Treatments
Description
The talk reviewed chronic inducible urticaria (CIU), emphasizing that it is defined by wheals triggered by specific physical or environmental stimuli and lasting more than six weeks, often overlapping with chronic spontaneous urticaria. Diagnosis depends heavily on a careful history plus provocation testing, since different subtypes—symptomatic dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory urticaria, cholinergic urticaria, contact urticaria, and aquagenic urticaria—can mimic one another and other skin or systemic disorders. The speaker highlighted the need to distinguish severe cold urticaria from autoinflammatory syndromes and to recognize that some forms may be life-threatening, especially when angioedema, respiratory, cardiovascular, or gastrointestinal symptoms occur. Disease assessment should use patient-reported outcomes such as the Urticaria Control Test, with additional subtype-specific tools when needed. Treatment follows the chronic urticaria stepwise approach: second-generation antihistamines first, often at increased doses, followed by biologics such as omalizumab, which has supportive evidence in several inducible subtypes, especially cold, solar, and dermographism; emerging options include dupilumab, remibrutinib, anti-Siglec-8 therapy, and KIT-directed agents. For solar urticaria, hardening/phototherapy may help, though sunscreen is often insufficient. Overall, the presentation stressed that CIU is heterogeneous, underpinned by incompletely understood mechanisms, and requires individualized diagnosis, monitoring, and treatment escalation to achieve complete control.
View moreConclusions
- Chronic inducible urticarias are defined by reproducible physical or environmental triggers and require careful history plus provocation testing for accurate diagnosis.
- CIndU frequently overlaps with chronic spontaneous urticaria, but patients with both conditions tend to have more active, longer-lasting, and more severe disease.
- The main diagnostic challenge is distinguishing specific inducible subtypes from close mimics such as exercise-induced anaphylaxis, urticarial vasculitis, polymorphous light eruption, and autoinflammatory syndromes.
- Validated provocation tests and threshold measurements are important not only for diagnosis but also for documenting treatment response and guiding follow-up.
- Patient-reported outcome tools, especially the Urticaria Control Test, are practical ways to assess disease control in both CSU and CIndU.
- Symptomatic dermographism and cold urticaria are relatively common inducible subtypes, while solar, aquagenic, and vibratory forms are rarer.
- Cold urticaria can be clinically dangerous in a subset of patients, particularly when it causes systemic reactions after cold-water exposure, so adrenaline use is sometimes warranted but appears underprescribed.
- Cholinergic urticaria and some atypical cold-urticaria forms are more heterogeneous than traditionally assumed, suggesting that patients’ reported triggers and presentations should be taken seriously.
- Current evidence suggests that mast-cell and IgE/FcεRI-related pathways are involved in CIndU, but the exact pathogenesis remains incompletely understood.
- The treatment goal for inducible urticaria should be complete control, not partial improvement.
- Management generally follows the same stepwise approach as CSU, starting with second-generation antihistamines and increasing doses up to fourfold before escalating therapy.
- Omalizumab is effective for many CIndU patients, especially in cold, solar, symptomatic dermographism, and delayed-pressure disease, but complete long-term remission is uncommon.
- Remibrutinib shows strong promise as a new oral BTK inhibitor for several CIndU subtypes and may work independently of whether patients respond to omalizumab.
- Dupilumab has not yet shown convincing efficacy in cold urticaria in phase 3 testing.
- Anti-KIT therapy such as barzolvolimab appears particularly potent, reducing mast-cell burden and improving thresholds, symptoms, and quality of life in cold urticaria and symptomatic dermographism.
- Emerging therapies targeting Siglec-8, BTK, KIT, and MRGPX2 reflect a shift toward mechanism-based treatment development in CIndU.
- Overall, the field still needs better phenotyping, deeper mechanistic understanding, and formal drug labeling for chronic inducible urticaria therapies.
- Zuberbier T et al. International Guideline for the Definition, Diagnosis and Management of Urticaria. Allergy 2026. doi: 10.1111/all.70210.#10.1111/all.70210
- Türk M et al. Identification of chronic urticaria subtypes using machine learning algorithms. Allergy 2022;77(1):323-326.#10.1111/all.15119
- Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CEH, Lawlor F, Mathieler-Fusade P, Meshkova RY, Zuberbier T, Metz M, Maurer M. Allergy 2016;71(6):780-802.
- Kulthanan K et al. Allergy 2026.
- Martínez-Escala M.E. et al. Acta Derm Venereol 2015;95:278-282.
- Abajian M. et al. Acta Derm Venereol 2016;96:56-59.
- Maurer M et al. J Allergy Clin Immunol 2018;141(2):638-49.
- Soegiharto R et al. Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study. Allergy 2025;80(2):489-499.#10.1111/all.16334
- Gimeno R. et al. Clinical and Translational Allergy 2023.
- Metz M A et al. J Allergy Clin Immunol Glob 2026 Feb 17;5(3):100673.
- Boyman et al.
- Deza et al.
- Kocaturk E. et al.
- Zuberbier T. et al.
- Mohammad-Porras N, González-Farré M, Andrades E, Pujol-Vallverdú RM, Barranco-Sanz C, Giménez Arnau A MD. EADV 2021.
- Terhorst-Molawi D et al. Anti-kit antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023 May;78(5):1269-1279.#10.1111/all.15585
- Altrichter et al. Journal of Allergy and Clinical Immunology.
- Wang et al. Frontiers in Immunology 2022.